Anthroposophic medicine is an integrative multimodal treatment system based on a holistic understanding of man and nature and of disease and treatment. It builds on a concept of four levels of formative forces and on the model of a three-fold human constitution. Anthroposophic medicine is integrated with conventional medicine in large hospitals and medical practices. It applies medicines derived from plants, minerals, and animals; art therapy, eurythmy therapy, and rhythmical massage; counseling; psychotherapy; and specific nursing techniques such as external embrocation. Anthroposophic healthcare is provided by medical doctors, therapists, and nurses. A Health-Technology Assessment Report and its recent update identified 265 clinical studies on the efficacy and effectiveness of anthroposophic medicine. The outcomes were described as predominantly positive. These studies as well as a variety of specific safety studies found no major risk but good tolerability. Economic analyses found a favorable cost structure. Patients report high satisfaction with anthroposophic healthcare.
VogelL. Der dreigliedrige Mensch.Dornach: Verlag am Goetheanum; 2005.
15.
SteinerR. Wesensglieder und Dreigliederung. In: Anthroposophische Leitsätze (32-34). Dornach 1925. Der Merkurstab.2007; (4):381.
16.
KienleGS, KieneH. “Beyond reductionism”—zur Notwendigkeit komplexer, organ-ismischer Ansätze in der Tumorimmunologie und Onkologie; in Kienle GS, Kiene H, editors. Die Mistel in der Onkologie.Stuttgart, NY: Schattauer Verlag; 2003: 333–432.
17.
KienleG, KieneH. From reductionism to holism: systems-oriented approaches in cancer research.Global Adv Health Med.2012; 1(5): 68–77.
18.
RosslenbroichB. Outline of a concept for organismic systems biology.Sem Cancer Biol.2011; 21(3): 156–164.
19.
SteinerR. Philosophy and anthroposophy (1904-1918).Whitefish: Kessinger Publishing, LLC; 2005.
20.
SteinerR. Monism and the philosophy of spiritual activity.Whitefish, MT: Kessinger Publishing; 2010.
21.
SteinerR. The philosophy of freedom: the basis for a modern world conception (1894).Forrest Row, UK: Rudolf Steiner Press; 2006.
22.
SteinerR. Der Kernpunkte der Sozialen Frage in den Lebensnotwendigkeiten der Gegenwart und Zukunft. (1919).Dornach, Switzerland: Rudolf Steiner Verlag; 1976.
23.
SteinerR. Aufsätze über die Dreigliederung des sozialen Organismus und zur Zeitlage 1915-1921.Dornach, Switzerland: Rudolf Steiner Verlag; 1982.
24.
AbouleishI. Sekem: A sustainable community in the Egyptian Desert.Edinburgh, Scotland: Floris Books; 2005.
25.
SteinerR. Spiritual science and medicine (1920).Forrest Row, UK: Rudolf Steiner Press; 1989.
26.
SteinerR, WegmanI. Fundamentals of therapy (1925).Forrest Row, UK: Rudolf Steiner Press; 1967.
27.
SchwabJH, MurphyJB, AnderssonPEurythmy therapy in anxiety—a case report.Altern Ther Health Med.2011; 17(4): 58–65.
28.
HeusserPH. Akademische Forschung in der Anthroposophischen Medizin.Beispiel Hygiogenese: Natur- und geisteswissenschaftliche Zugänge zur Selbstheilungskraft des Menschen. Bern, Switzerland: Peter Lang AG; 1999.
GutenbrunnerC, HildebrandtG, MoogRChronobiology and Chronomedicine: Basic Research and Applications. Proceedings of the 7th Annual Meeting of the European Society for Chronobiology, Marburg 1991.Frankfurt am Main, Berlin: Peter Lang; 1991.
31.
GirkeM. Innere Medizin. Grundlagen und therapeutische Konzepte der Anthroposophischen Medizin.Berlin: Salumed-Verlag GmbH; 2010.
32.
SoldnerG, StellmannHM. Individuelle Pädiatrie: Leibliche, seelische und geistige Aspekte in Diagnostik und Beratung. Anthroposophisch-homöopathische Therapie.Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2007.
33.
Institute of Medicine.Integrative medicine and the health of the public: a summary of the February 2009 summit.Washington, DC: The National Academies Press; 2009.
34.
BurkhardtR, KienleG: Die Zulassung von Arneimitteln und der Widerruf von Zulassungen nach dem Arzneimittelgesetz von 1976; Stuttgart: Verlag Urachhaus;1982.
35.
HauschkaM. Zur künstlerischen Therapie Bd.II. Wesen und Aufgabe der Maltherapie.Nürnberg, Germany: Karl Ulrich & Co; 1991.
HamreHJ, FischerM, HegerMAnthroposophic vs conventional therapy of acute respiratory and ear infections: a prospective outcomes study.Wien Klin Wochenschr.2005; 117(7-8): 258–68.
41.
ZieglerR. Mistletoe preparation Iscador: are there methodological concerns with respect to controlled clinical trials?Evid Based Complement Alternat Med.2009 Mar; 6(1): 19–30.
42.
KienleGS, GlockmannA, GrugelRKlinische Forschung zur Anthroposophischen Medizin—Update eines Health Technology Assessment-Berichts und Status Quo.Forsch Komplementmed.2011; 18: 269–82.
43.
HekalIA, SamerT, IbrahimEI. Viscum Fraxini 2, as an adjuvant therapy after resection of superficial bladder cancer: prospective clinical randomized study. Presented at the 43rd Annual Congress of The Egyptian Urological Association in conjunction with The European Association of Urology November 10-14, 2008, Hurghada, Egypt. Abstract P8. 120. 2009.
44.
MolassiotisA, Fernandez-OrtegaP, PudDUse of complementary and alternative medicine in cancer patients: a European survey.Ann Oncol.2005; 16(4): 655–63.
45.
FaschingPA, ThielF, Nicolaisen-MurmannKAssociation of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies.Support Care Cancer.2007; 55(11): 1277–84.
46.
KienleGS, KieneH. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen.Stuttgart, NY: Schattauer Verlag; 2003.
47.
BüssingA editor. Mistletoe: the genus Viscum.Amsterdam: Hardwood Academic Publishers; 2000.
48.
OrhanDD, KupeliE, YesiladaEAnti-inflammatory and antinociceptive activity of flavonoids isolated from Viscum album ssp. album.Z Naturforsch C.2006; 61(1-2): 26–30.
49.
WinklerK, LeneweitG, SchubertR. Characterization of membrane vesicles in plant extracts.Colloids Surf B Biointerfaces.2005; 45(2): 57–65.
50.
JagerS, WinklerK, PfullerUSolubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L.Planta Med.2007; 73(2): 157–162.
51.
EggenschwilerJ, vonBL, StrittBMistletoe lectin is not the only cyto-toxic component in fermented preparations of Viscum album from white fir (Abies pectinata).BMC Complement Altern Med.2007May 10; 7: 14.
52.
BüssingA, SchietzelM. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins.Anticancer Res.1999; 19(1A):23–8.
53.
Elsässer-BeileU, LusebrinkS, GrussenmeyerUComparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes.Arzneim Forsch/Drug Res.1998; 48(II)(12):1185–9.
54.
ValentinerU, PfüllerU, BaumCThe cytotoxic effect of mistletoe lec-tins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro.Toxicology.2002; 171(2-3): 187–99.
55.
SiegleI, FritzP, McClellanMCombined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells.Anticancer Res.2001; 21(4A):2687–91.
56.
BantelH, EngelsIH, VoelterWMistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis.Cancer Res.1999; 59: 2083–90.
57.
MuellerEA, AndererFA. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: Chemical specificity of target cell recognition.Cancer Res.1990; 50: 3646–51.
58.
ZhuHG, ZollnerTM, Klein-FrankeAEnhancement of MHC-unrestricted cyto-toxic activity of human CD56+CD3-natural killer (NK) cells and CD+T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets.J Cancer Res Clin Oncol.1994; (120):383–8.
59.
KienleGS, KieneH. Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies.Integr Cancer Ther.2010; 9(2): 142–57.
60.
KienleGS, BerrinoF, BüssingAMistletoe in cancer—a systematic review on controlled clinical trials.Eur J Med Res.2003; 8(3): 109–19.
61.
KienleGS, KieneH. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts.Eur J Med Res.2007; 12(3): 103–19.
62.
TrögerW, GalunD, ReifM, SchumannA, StankovicN, MilicevicM. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival.Eur J Cancer.2013; In press.
63.
KienleGS, GlockmannA, SchinkMViscum album L. extracts in breast and gynaecologic cancers: a systematic review of clinical and preclinical research.J Exp Clin Cancer Res.2009 Jun 11;28:79.
64.
MabedM, El-HelwL, SharmaS. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.Br J Cancer.2004; 90(1): 65–9.
65.
MatthesH, BuchwaldD, SchadFTreatment of inoperable pancreatic carcinoma with combined intratumoral mistletoe therapy.Gastroenterology.2005; 128(4 Suppl 2):433.
66.
OrangeM, FonsecaM, LaceADurable tumour responses following primary high dose induction with mistletoe extracts: two case reports.Eur J Integr Med.2010; 2(2): 63–9.
67.
OrangeM, LaceA, FonsecaMDurable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment—two case reports.Global Adv Health Med.2012; 1(1): 16–23.
68.
WerthmannP, SträterG, FrieslandHDurable response of cutaneous squamous cell carcinoma following high-dose perilesional injections of Viscum album extracts—a case report.Phytomedicine.2013; 20(3-4): 324–7.
69.
KienleGS, GrugelR, KieneH. Safety of higher dosages of Viscum album L. in animals and humans - systematic review of immune changes and safety parameters.BMC Complement Altern Med.2011; 11(1): 72.
70.
HamreHJ, Becker-WittC, GlockmannA, ZieglerR, WillichSN, KieneH. Anthroposophic therapies in chronic disease: the Anthroposophic Medicine Outcome Study (AMOS).Eur J Med Res.2004; 9(7): 351–360.
71.
HamreHJ, WittCM, KienleGSAnthroposophic therapy for children with chronic disease: a two-year prospective cohort study in routine outpatient settings.BMC Pediatr2009 Jun 19; 9:39.
72.
HamreHJ, WittCM, GlockmannA, ZieglerR, WillichSN, KieneH. Eurythmy therapy in chronic disease: a four-year prospective cohort study.BMC Public Health2007Apr 23; 7: 61.
73.
HamreHJ, WittCM, GlockmannA, ZieglerR, WillichSN, KieneH. Anthroposophic art therapy in chronic disease: a four-year prospective cohort study.Explore NY.2007; 3(4): 365–71.
HamreHJ, WittCM, GlockmannA, ZieglerR, WillichSN, KieneH. Anthroposophic medical therapy in chronic disease: a four-year prospective cohort study.BMC Complement Altern Med2007Apr 23; 7: 10.
76.
HamreHJ, WittCM, GlockmannAOutcome of anthroposophic medication therapy in chronic disease: a 12-month prospective cohort study.Drug Des Devel Ther.2009Feb 6; 2: 25–37.
77.
HamreHJ, WittCM, KienleGSAnthroposophic therapy for children with attention deficit hyperactivity: a two-year prospective study in outpatients.Int J Gen Med.2010Aug 30; 3: 239–53.
78.
HamreHJ, WittCM, KienleGSAnthroposophic therapy for anxiety disorders: a two-year prospective cohort study in routine outpatient settings.Clin Med Insights: Psychiatry.2009; 2: 17–31.
79.
HamreHJ, WittCM, KienleGSAnthroposophic therapy for asthma: a two-year prospective cohort study in routine outpatient settings.J Asthma Allergy.2009Nov 24; 2: 111–28.
80.
HamreHJ, WittCM, GlockmannA, ZieglerR, WillichSN, KieneH. Anthroposophic therapy for chronic depression: a four-year prospective cohort study.BMC Psychiatry.2006Dec 15; 6: 57.
81.
HamreHJ, WittCM, GlockmannAAnthroposophic vs conventional therapy for chronic low back pain: a prospective comparative study.Eur J Med Res.2007; 12(7): 302–10.
82.
HamreHJ, WittCM, KienleGSLong-term outcomes of anthroposophic therapy for chronic low back pain: A two-year follow-up analysis.J Pain Res.2009Jun 25; 2: 75–85.
83.
HamreHJ, WittCM, KienleGSAnthroposophic therapy for migraine: a two-year prospective cohort study in routine outpatient settings.Open Neurol J.2010; 4: 100–10.
84.
HamreHJ, GlockmannA, TrögerW, KienleGS, KieneH. Assessing the order of magnitude of outcomes in single-arm cohorts through systematic comparison with corresponding cohorts: an example from the AMOS study.BMC Med Res Methodol.2008; 8: 11.
HeusserP, BraunSB, ZieglerRPalliative inpatient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine.Forsch Komplementmed.2006; 13(2): 94–100.
87.
HeusserP, Berger BraunS, BertschyMPalliative inpatient cancer treatment in an anthroposophic hospital: II.Quality of life during and after stationary treatment, and subjective treatment benefits. Forsch Komplementmed2006; 13(3): 156–66.
88.
von RohrE, PampallonaS, van WegbergBExperiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer.Schweiz Med Wochenschr.2000; 130(34): 1173–84.
89.
von RohrE, PampallonaS, van WegbergBAttitudes and beliefs towards disease and treatment in patients with advanced cancer using anthroposophical medicine.Onkologie2000; 23: 558–563.
90.
CarlssonM, ArmanM, BackmanM, FlattersU, HatschekT, HamrinE. Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care.Acta Oncol.2004; 43(1): 27–34.
91.
CarlssonM, ArmanM, BackmanM, FlattersU, HatschekT, HamrinE. A five-year follow-up of quality of life in women with breast cancer in anthroposophic and conventional care.Evid Based Complement Alternat Med2006; 3(4): 523–31.
92.
SimonL. Ein anthroposophisches Therapiekonzept für entzündlich-rheumatische Erkrankungen. Ergebnisse einer zweijährigen Pilotstudie.Forsch Komplementmed.1997; 4: 17–27.
93.
AstrupC, AstrupSv, AstrupSDie Behandlung von Gesichtsschmerzen mit homöopathischen Heilmitteln.Erfahrungsheilkunde.1976; 3: 89–96.
94.
SchäferPM: Katamnestische Untersuchung zur Anorexia nervosa. In: BisseggerM, editor. Die Behandlung von Magersucht: ein integrativer Therapieansatz.Stuttgart: Verlag Freies Geistesleben; 1998: 130–60.
95.
HuberR, LüdtkeR, KlassenMEffects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.Eur J Med Res.2001; 6(9): 399–405.
96.
TuseniusKJ, SpoekJM, KramersCW. Iscador Qu for chronic hepatitis C: an exploratory study.Complement Ther Med.2001; 9(1): 12–6.
97.
TuseniusKJ, SpoekAM, vanHJ. Exploratory study on the effects of treatment with two mistletoe preparations on chronic hepatitis C.Arzneimittelforschung.2005; 55(12): 749–53.
98.
HuykeC, LaszczykK, SchefflerABehandlung aktinischer Keratose mit Birkenkorkenextrakt: Eine Pilotstudie.J Dtsch Dermatol Ges.2006; 4(2): 132–6.
99.
HuykeC, ReuterJ, RodigMTreatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study.J Dtsch Dermatol Ges.2008.
100.
OstermannT, BlaserG, BertramM, MichalsenA, MatthiessenPF, KraftK. Effects of rhythmic embrocation therapy with solum oil in chronic pain patients: a prospective observational study.Clin J Pain.2008; 24(3): 237–43.
101.
BaarsEW, GansS, EllisEL. The effect of hepar magnesium on seasonal fatigue symptoms: a pilot study.J Altern Complement Med.2008; 14(4): 395–402.
102.
GualaA, PastoreG, GaripoliV, AgostiM, VitaliM, BonaG. The time of umbilical cord separation in healthy full-term newborns: a controlled clinical trial of different cord practices.Eur J Pediatr.2003; 162(5): 350–1.
MajorekM, TüchelmannT, HeusserP. Therapeutic eurythmy—movement therapy for children with attention deficit hyperactivity disorder (ADHD): a pilot study.Complement Ther Nurs Midwifery.2004 Feb; 10(1): 46–53.
105.
UlbrichtM. Antipyretische Wirkung eines körperwarmen Einlaufes. Inaugural-Dissertation.Tübingen;1991.
106.
GärtnerC. Therapie der Arthrosen grosser Gelenke.Merkurstab.1999; 1: 48–51.
107.
GärtnerC. Der akute muskuläre Okzipitalschmerz. Therapiestudie mit lokalen Infil-trationen Gelsemium compositum.Merkurstab.1999; 4: 244–9.
108.
KrabbeAA, OlesenJ. Ferrumkvarts som profylaktikum ved migræne. En dobbelt-blind unders⊘gelse.Ugeskr Laeger.1980; 142(8): 516–8.
109.
JeffreySLA, BelcherJC. Use of Arnica to relieve pain after carpal-tunnel release surgery.Altern Ther Health Med.2002; 8(2): 66–8.
110.
PachD, BrinkhausB, RollSEfficacy of injections with Disci/Rhus Toxi-codendron Compositum for chronic low back pain—a randomized placebo-controlled trial.PLoS ONE.2011; 6(11): e26166.
111.
HuberR, PrestelU, BlossI, MeyerU, LüdtkeR. Effectiveness of subcutaneous injections of a cartilage preparation in osteoarthritis of the knee—a randomized, placebo controlled phase II study.Complement Ther Med.2010; 18(3): 113–8.
112.
SharpL, FinniläK, JohanssonH, AbrahamssonM, HatschekT, BergenmarM. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions—results from a randomised blinded trial.Eur J Oncol Nurs.2013 Aug; 17(4): 429–35.
113.
von HagensC, SchillerP, GodbillonBTreating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial.Climacteric2012; 15(4): 358–67.
114.
EschBM, MarianF, BusatoA, HuesserP. Patient satisfaction with primary care: an observational study comparing anthroposophic and conventional care.Health Qual Life Outcomes.2008; 6(1): 74.
HamreHJ, WittCM, GlockmannA, TrögerW, WillichSN, KieneH. Use and safety of anthroposophic medications in chronic disease: a 2-year prospective analysis.Drug Saf.2006; 29(12): 1173–89.
117.
BaarsEW, Adriaansen-TennekesR, EikmansKJ. Safety of homeopathic injectables for subcutaneous administration: a documentation of the experience of prescribing practitioners.J Altern Complement Med.2005; 11(4): 609–16.
118.
HamreHJ, GlockmannA, FischerMUse and safety of anthroposophic medications for acute respiratory and ear infections: a prospective cohort study.Drug Target Insights.2007; 2: 209–19.
119.
JeschkeE, OstermannT, LukeCRemedies containing Asteraceae extracts: a prospective observational study of prescribing patterns and adverse drug reactions in German primary care.Drug Saf.2009; 32(8): 691–706.
120.
PlanggerN, RistL, ZimmermannR, von MandachU. Intravenous tocolysis with Bryophyllum pinnatum is better tolerated than beta-agonist application.Eur J Obstet Gynecol Reprod Biol.2006; 124(2): 168–72.
121.
HamreHJ, WittCM, GlockmannAHealth costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings.Eur J Health Econ.2010; 11(1): 77–94.
122.
HamreHJ, WittCM, GlockmannA, ZieglerR, WillichSN, KieneH. Health costs in anthroposophic therapy users: a two-year prospective cohort study.BMC Health Services Research.2006; 6: 65.
123.
StuderHP, BusatoA. Comparison of Swiss basic health insurance costs of complementary and conventional medicine.Forsch Komplementmed.2011; 18(6): 315–20.
124.
StuderHP, BusatoA. Development of costs for complementary medicine after provisional inclusion into the Swiss basic health insurance.Forsch Komplementmed.2011; 18(1): 15–23.
125.
KooremanP, BaarsEW. Patients whose GP knows complementary medicine tend to have lower costs and live longer.Eur J Health Econ.2012 Dec; 13(6): 769–76.
126.
KienleGS. Why medical case reports?Global Adv Health Med.2012; 1(1): 8–9.
127.
KienleGS, KieneH. Clinical judgement and the medical profession.J Eval Clin Pract.2011; 17(4): 621–7.
128.
KieneH, Schön-AngererT. Single-case causality assessment as a basis for clinical judgment.Altern Ther Health Med.1998; 4(1): 41–47.
KieneH, HamreHJ, KienleGS. In support of clinical case reports: a system of causality assessment.Global Adv Health Med.2013; 2(2): 28–39.
131.
WodeK, SchneiderT, LundbergI, KienleGS. Mistletoe treatment in cancer-related fatigue: a case report.Cases J.2009Jan 22; 2(1): 77.
132.
KienleGS, MeusersM, QueckeB, HilgardD. Patient-centered diabetes care in children: an integrated, individualized, systems-oriented, and Multidisciplinary Approach.Global Adv Health Med2013; 2(2): 12–19.
